Tyra Biosciences, Inc.

Tyra Biosciences, Inc. (TYRA) priced its initial public offering on Sep 15, 2021 at $16.00 per share, raising $172.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $654.6M. BofA Securities was lead-left underwriter, joined by Jefferies and TD Cowen. Latham & Watkins advised the company and Sidley Austin advised the underwriters.

Tyra Biosciences, Inc. is a precision oncology company developing therapies to overcome tumor resistance to targeted treatments such as kinase inhibitors. It uses its proprietary SNAP platform to refine drug candidates for patients with cancer.

Status

IPO

Ticker

TYRA

Exchange

Nasdaq Global Select

Priced

Sep 15, 2021

IPO price

$16.00

Raised

$172.8M

Market cap at IPO price

$654.6M

First filed

Aug 20, 2021

Underwriters

BofA Securities, Jefferies and TD Cowen

Company counsel

Latham & Watkins

Underwriters' counsel

Sidley Austin

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.